The Pharmaceutical Company, officially known as the Saudi Pharmaceutical and Medical Supplies Company, is one of the oldest pharmaceutical companies in the Kingdom of Saudi Arabia. It stands out as a pivotal name in the Saudi financial market, representing a fundamental pillar in supporting local self-sufficiency in pharmaceuticals. Established in the 1980s, the company manufactures and distributes medicines and medical supplies to hospitals and pharmacies in the Saudi market. With the growing interest in the healthcare sector under Saudi Vision 2030, the Pharmaceutical Company is rising to be at the forefront of local manufacturers, enhancing its position through product expansion and adopting high-quality standards. In this article, we will detail the performance of the Pharmaceutical Company in the Saudi financial market, key financial indicators, challenges it faces, its competitors, and its most important recent developments, in addition to answering the most frequently asked questions about its stock and symbol (2070) on Tadawul. We will adopt a neutral educational approach, focusing on providing a clear picture to help the reader understand the Pharmaceutical Company's position in the Saudi healthcare sector.
History and Establishment of the Pharmaceutical Company
The Pharmaceutical Company, or the Saudi Pharmaceutical and Medical Supplies Company, was established in the 1980s, benefiting from the national trend towards enhancing self-sufficiency in vital products, primarily medicines and medical supplies. Since its inception, the company has focused on local manufacturing of ready-to-use medicines and daily-use medical supplies. The Pharmaceutical Company was among the first to embody the partnership between the public and private sectors, playing a pivotal role in supplying government and security hospitals with essential medicines. Over the decades, the company has evolved by expanding its production lines and introducing new products that align with the evolving needs of the Saudi market. Today, the Pharmaceutical Company continues to solidify its position as a strategic supplier of medicines amidst a developing regulatory environment and increasing government support for the pharmaceutical industry.
Core Activity and Main Products
The Pharmaceutical Company offers a wide range of pharmaceutical products and medical supplies that meet the needs of hospitals, pharmacies, and healthcare institutions. Its product line includes ready-to-use medicines such as tablets, liquids, and antibiotics, as well as injection equipment and essential medical tools. The company relies heavily on local manufacturing, giving it a competitive advantage in meeting rapid demand and providing tailored solutions for the Saudi market. Its activities also include research and development to improve product quality and expand its pharmaceutical portfolio, in addition to supplying government entities, especially the Ministry of Health, with large contracts for essential medicines. This product diversity allows the Pharmaceutical Company to maintain a strong foothold in a market that is witnessing increasing competition and a continuous need for innovation and quality.
Pharmaceutical Company’s Position in the Saudi Stock Market
The Pharmaceutical Company is listed on the Saudi financial market (Tadawul) under the symbol (2070), occupying a strategic position within the pharmaceutical industry sector. This sector is one of the vital sectors supported by the government, witnessing sustainable growth driven by rising local demand and policies supporting local content. The Pharmaceutical Company's stock appears on the mid-cap stock list and is often monitored by investors interested in the healthcare sector. The stock's performance and further details can be tracked through its page on Tadawul: Pharmaceutical Company Stock 2070.
Key Financial Indicators for Pharmaceutical Stock
The latest financial indicators for the Pharmaceutical stock include:
- Stock Price: Approximately 23.00 SAR in mid-2025.
- Market Capitalization: Estimated in billions (forecast between 3 to 5 billion SAR, depending on the number of shares).
- Price-to-Earnings Ratio (P/E): Not officially announced, but estimated to be high due to low profits or modest earnings in 2024.
- Dividends: The company did not distribute dividends for the year 2024, according to the board's recommendation.
- Revenue Growth: Preliminary results for Q1 2025 indicate continued operational activity.
These indicators reflect the company's position during a period focused on enhancing its financial solvency while maintaining liquidity to face operational challenges.
Dividend Distribution Analysis and Company Policy
The Pharmaceutical Company follows a conservative dividend distribution policy based on the board's assessment of cash flows and the company's profitability. In 2024, the board recommended not to distribute cash dividends to shareholders, reflecting pressures on profitability or a trend to retain liquidity to support growth or face challenges. In previous years, the company may have distributed between 5-10% of the nominal value of the share, depending on financial performance. The decision to distribute dividends is primarily based on the company's annual results and its investment commitments. The announcement of no distribution in 2024 is an indicator of financial prudence, not necessarily a permanent policy, as the policy may change in light of improved financial performance in the coming years.
Pharmaceutical Industry Sector in Saudi Arabia
The pharmaceutical industry sector in Saudi Arabia is witnessing sustainable growth driven by increasing local demand and government trends to enhance local manufacturing under Vision 2030. The Kingdom aims to raise the self-sufficiency rate of medicines and medical supplies and reduce reliance on imports. The Pharmaceutical Company competes with local and global companies for government supply contracts, while regulatory policies such as price controls and essential drug lists put pressure on profit margins. The Saudi Food and Drug Authority imposes high standards for quality and safety, enhancing the credibility of local companies but increasing the cost of developing new products. The Pharmaceutical Company plays an active role in implementing these national strategies, making it an important part of the Saudi healthcare system.
Pharmaceutical Company Competitors in the Local Market
The Pharmaceutical Company competes with several local companies in the pharmaceutical industry, including:
- Jamjoom Pharmaceutical Factory (part of Tamer Group)
- Eastern Pharmaceutical Industries
In addition to global companies active in the Saudi market. Competition is focused on government contracts and supplying medicines to hospitals, where technical testing and the ability to manufacture locally are key competitive advantages. Competition in developing new products is also increasing, as entering the Saudi market requires strict regulatory approvals. The Pharmaceutical Company remains competitively positioned due to its long experience and product diversity, but it faces ongoing challenges from local and international competitors.
Pharmaceutical Stock Performance on Tadawul
The Pharmaceutical stock is listed on Tadawul under the symbol 2070 and is classified among mid-cap stocks in the pharmaceutical industry sector. The stock price reached approximately 23 SAR in one of the sessions in mid-2025, influenced by the company's financial performance and general market conditions. The company did not announce a dividend distribution for 2024, which affected the stock's attractiveness to some investors seeking regular income. However, the stock remains monitored by investors interested in the growth of the healthcare sector. Stock data and developments can be tracked directly from the official Tadawul page.
Administrative Developments and Governance in the Pharmaceutical Company
The Pharmaceutical Company has witnessed several important administrative developments during 2024 and 2025, most notably the formation of internal oversight committees and the appointment of a chairman and deputies along with audit committees. These steps reflect the company's commitment to enhancing transparency and governance in line with best practices in the Saudi financial market. The company has also invited its shareholders to attend the general assembly via modern technology, indicating a trend towards greater openness and transparency in decision-making. These administrative measures enhance investor confidence and support the company's long-term stability.
Factors Affecting Pharmaceutical Performance
The performance of the Pharmaceutical Company is influenced by several internal and external factors, including:
- Government policies supporting local manufacturing
- Fluctuations in raw material prices
- Competition with local and global companies
- Development of regulatory frameworks by the Food and Drug Authority
- Changes in government health spending budgets
- Global trends in the pharmaceutical industry and innovation
These factors collectively play a role in determining the company's profitability and growth, as success in the sector requires the ability to continuously adapt to changes.
Pharmaceutical Company's Role in Achieving Saudi Vision 2030
The Pharmaceutical Company directly contributes to achieving the goals of Saudi Vision 2030, particularly regarding enhancing self-sufficiency in vital industries. The company supports the national trend to increase local manufacturing of medicines and reduce reliance on imports, thereby enhancing the Kingdom's pharmaceutical security. The Pharmaceutical Company also participates in developing national competencies and providing job opportunities, seeking to enhance research and development in the pharmaceutical sector. This role represents a strategic pivot that elevates the company's value in the local market and supports its position within the national economy.
Challenges and Future Opportunities for the Pharmaceutical Company
The Pharmaceutical Company faces key challenges including rising costs of developing new products, stringent quality requirements, and competitive pressures from global suppliers. Conversely, government policies supporting local manufacturing open opportunities to expand market share, especially with increased tariffs on imported products and larger contracts allocated to local producers. Additionally, the continuous growth in demand for healthcare presents opportunities for innovation in new products and service development. The success of the Pharmaceutical Company in capitalizing on these opportunities depends on its ability to innovate and continuously develop its production lines.
Recent News and Announcements about the Pharmaceutical Company
Recently, several official announcements from the Pharmaceutical Company have been highlighted through the Tadawul platform, including:
- Preliminary financial results for Q1 2025 showing continued operational activity.
- Invitation to the first ordinary general assembly in 2025 via modern technology.
- Formation of oversight committees and new administrative appointments reflecting a trend towards enhancing governance.
- The board's recommendation not to distribute dividends for 2024 to support financial solvency.
These developments reflect the company's focus on operational and administrative stability in the face of sector challenges.
Conclusion
The Pharmaceutical Company is one of the leading companies in the Saudi pharmaceutical industry, playing an important role in enhancing national pharmaceutical security through local manufacturing and supplying major healthcare institutions. The company has faced challenges in recent years regarding profitability and dividend distributions, yet it has continued to develop its organizational structure and update its strategies to keep pace with changes in the sector. With ongoing government support and increasing demand for healthcare products, the Pharmaceutical Company remains positioned for future growth, especially if it succeeds in enhancing its competitive and innovative capabilities. Always remember the importance of following official financial news from reliable sources such as the Tadawul platform, and for in-depth analysis or evaluation of investment opportunities that align with your goals, it is advisable to consult a licensed financial advisor. The SIGMIX platform provides you with the tools and data to support your informed financial decisions.
Frequently Asked Questions
The Pharmaceutical Company is the Saudi Pharmaceutical and Medical Supplies Company, specializing in the local production of ready-to-use medicines and medical supplies. Established in the 1980s, it is one of the largest suppliers to the Ministry of Health and Saudi hospitals. Its products include liquid medicines, tablets, antibiotics, and basic medical equipment. It aims to support pharmaceutical self-sufficiency in the Kingdom.
The Pharmaceutical Company's stock is traded on the Saudi financial market (Tadawul) under the symbol (2070). You can track the stock's performance and data through the company's official page on the Tadawul platform.
The Pharmaceutical stock price reached approximately 23.00 SAR in mid-2025. The stock price is influenced by the company's financial results, dividend distribution policies, changes in the healthcare sector, and local and global competition. Regulatory and economic changes also play a role in stock price movements.
In 2024, the Pharmaceutical Company's board recommended not to distribute cash dividends to shareholders to support liquidity and financial solvency. The distribution policy depends on the annual results and the company's commitments and may change in the future based on financial performance.
Key challenges include rising costs of developing new products, competition with local and global companies, stringent quality requirements from the Saudi Food and Drug Authority, and changes in government health spending budgets. These factors require the company to be flexible and continuously develop to maintain its competitiveness.
The Pharmaceutical Company competes with companies such as Jamjoom Pharmaceutical Factory and Eastern Pharmaceutical Industries, in addition to global companies. Competition focuses on government contracts, product quality, and the development of new medicines.
The Pharmaceutical Company contributes to achieving Vision 2030 by enhancing local manufacturing of medicines, reducing reliance on imports, developing national competencies, and providing job opportunities in vital industries. It plays a role in supporting pharmaceutical security and achieving self-sufficiency for the Kingdom.
Following official news allows investors to stay informed about the company's performance, financial results, administrative changes, and dividend distribution policies. This information helps form a clear picture of the company and sector conditions, supporting informed financial decision-making.
Market capitalization is calculated by multiplying the stock price by the number of issued shares. The price-to-earnings ratio (P/E) is calculated by dividing the stock price by the annual earnings per share. In cases of low or absent profits, the P/E ratio increases, indicating the stock's valuation compared to the company's earnings.
Future growth opportunities include increasing government contracts, expanding new products, benefiting from government support for local manufacturing, and rising demand for healthcare. The Pharmaceutical Company's success in capitalizing on these opportunities depends on its innovation and continuous development of production lines.